"10.1371_journal.pone.0142612","plos one","2015-11-23T00:00:00Z","Estelle Daudigeos-Dubus; Ludivine Le Dret; Claudia Lanvers-Kaminsky; Olivia Bawa; Paule Opolon; Albane Vievard; Irène Villa; Mélanie Pagès; Jacques Bosq; Gilles Vassal; Dieter Zopf; Birgit Geoerger","Université Paris-Sud 11, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France; CNRS, Vectorology and Anticancer Therapeutics, UMR 8203, Orsay, France; Gustave Roussy, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France; University Children’s Hospital, Department of Pediatric Hematology and Oncology, Münster, Germany; PFEP (Plateforme d’évaluation préclinique), Gustave Roussy, Villejuif, France; Tribvn, Châtillon, France; Pathology Laboratory, Gustave Roussy, Villejuif, France; Department of Neuropathology, Sainte-Anne’s Hospital, Paris, France; Paris Descartes University, Paris, France; Bayer Pharma Aktiengesellschaft, Berlin, Germany","Conceived and designed the experiments: EDD CLK DZ BG. Performed the experiments: EDD LLD CLK OB AV IV MP. Analyzed the data: ED CLK PO AV MP DZ BG. Contributed reagents/materials/analysis tools: DZ AV JB PO MP. Wrote the paper: ED BG DZ CLK OB PO AV MP GV. Designed the software used in the analysis, in a collaborative manner without funding: AV.","The authors have the following interests: This study was supported by Bayer Pharma Aktiengesellschaft. Co-author Dieter Zopf is employed by Bayer Pharma Aktiengesellschaft. Co-author Albane Vievard is employed by Tribvn. There are no patents, products in development or marketed products to declare. This does not alter their adherence to all the PLOS ONE policies on sharing data and materials as detailed online in the guide for authors. All other authors have no conflict to interest to declare.","2015","11","Estelle Daudigeos-Dubus","EDD",12,TRUE,4,7,7,9,TRUE,TRUE,FALSE,0,NA,FALSE
